

SGLT2 medicines for heart failure

Jardiance (empagliflozin) and Farxiga (dapagliflozin)

Jardiance (empagliflozin) and Farxiga (dapagliflozin) are alternatives for heart failure across ejection fractions (EF), with or without diabetes. Usual HF dose: 10 mg once daily, with or without food. Take only one. [\[12\]](#) [\[13\]](#) [\[14\]](#) [\[15\]](#)

What benefit was seen?

Medicine or placebo was added to usual care. Outcomes: cardiovascular death/HF admission; dapagliflozin also counted urgent HF visits needing IV treatment. [\[1\]](#) [\[2\]](#) [\[3\]](#) [\[4\]](#)

People with the combined outcome; median follow-up

Trial / population / time	Medicine	Placebo
Jardiance: EMPEROR-Reduced EF ≤40%; 16 months	361/1,863 (19.4%)	462/1,867 (24.7%) [1]
Farxiga: DAPA-HF EF ≤40%; 18.2 months	386/2,373 (16.3%)	502/2,371 (21.2%) [2]
Jardiance: EMPEROR-Preserved EF >40%; 26.2 months	415/2,997 (13.8%)	511/2,991 (17.1%) [3]
Farxiga: DELIVER EF >40%; 2.3 years	512/3,131 (16.4%)	610/3,132 (19.5%) [4]

About 3–5 fewer people per 100 had these outcomes, mainly fewer HF hospital visits. These are not yearly risks or direct drug comparisons; not every trial proved longer survival. [\[1\]](#) [\[2\]](#) [\[3\]](#) [\[4\]](#)

Commonly reported problems

More urination, genital yeast infection and dizziness from fluid loss can occur. Urinary and genital infections differ. [\[12\]](#) [\[13\]](#)

EMPEROR-Reduced: 1,863 treated people per group

Reported event	Jardiance	Placebo
Genital infection	1.7%	0.6% [5]
Urinary tract infection	4.9%	4.5% [5]
Fluid depletion	10.6%	9.9% [5]

Collected through 7 days after stopping; median 16 months. Farxiga HF trials did not collect every mild infection, preventing direct comparison. Report itching, discharge, burning urination or persistent dizziness. [\[5\]](#) [\[2\]](#) [\[8\]](#)

How often did people stop?

Reduced-EF trials: permanent stops, medicine versus placebo

Definition / trial	Medicine	Placebo
Any reason except death DAPA-HF, 18.2 months	249/2,373 (10.5%)	258/2,371 (10.9%) [2]
Any reason except death EMPEROR-Reduced, 16 months	303/1,863 (16.3%)	335/1,863 (18.0%) [1]
Adverse event: DAPA-HF	111/2,368 (4.7%)	116/2,368 (4.9%) [2] [6]

Reported problems need not be drug-caused. A Korean cohort estimated 7.5% stopped by one year for various reasons; this is not a US or drug-specific prediction. [\[2\]](#) [\[1\]](#) [\[11\]](#)

Daily, pause and urgent-care plan

Before starting: kidney tests and water-pill review. Take the prescribed 10 mg daily. Do not adjust insulin yourself. [\[12\]](#) [\[13\]](#)

Pause: hold during vomiting, dehydration or inability to eat/drink and contact your team. Hold at least three days before surgery/prolonged fasting. Restart when your team confirms you are stable and eating/drinking. [\[12\]](#) [\[13\]](#)

Urgent: stop and seek care for nausea/vomiting with belly pain, unusual weakness or difficult breathing. Dangerous acid buildup can occur without high glucose. Genital/perineal pain or swelling with fever also needs urgent care. Discuss type 1 diabetes or a ketogenic diet before use. Call if pregnant and avoid breastfeeding. [\[12\]](#) [\[13\]](#)

What might I pay out of pocket?

US examples checked September 5, 2026; confirm your quote

Payment route	Price and conditions
GoodRx coupon/cash: 10 mg x30 / 30 days	Generic dapagliflozin \$20.15; Jardiance \$249 cash offer. Pharmacy/eligibility vary. [16] [18] [19]
Blueberry cash	Generic dapagliflozin 10 mg: \$25.30 advertised 90-day supply. Confirm quantity and all fees. No public Jardiance quote verified. [20] [21]
Typical insured benchmark	Employer-plan tier 1/2/3 averages: \$12/\$40/\$71; not either drug's copay (KFF 2025, plans with 3+ tiers). [22]

Medicare 2026: plan-specific costs; maximum deductible \$615 and \$2,100 yearly Part D out-of-pocket cap, excluding premiums. Extra Help, if eligible: generally at most \$5.10 generic/\$12.65 brand per covered prescription. Cash outside Part D does not count toward its deductible/cap. [\[24\]](#) [\[25\]](#)